Dermis disorder

This study aimed to find a safe dose of a custom-made mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine was designed to train the immune system to attack the cancer. However, the trial was withdrawn before any participants were enrolled.

This early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This phase II trial tests whether adding the immunotherapy drug nivolumab to the chemotherapy paclitaxel helps shrink tumors in people with angiosarcoma who haven't had taxane drugs before. For those who have already received taxanes, the trial tests a combination of nivolumab an…

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…

This phase III trial tests whether the immunotherapy drug pembrolizumab can prevent Merkel cell cancer from returning after it has been surgically removed. About 280 adults with stage I-III Merkel cell cancer are randomly assigned to receive either pembrolizumab or standard obser…

This phase 2 trial tests whether adding tuvusertib (a drug that blocks a DNA repair enzyme) to avelumab (an immunotherapy) can slow cancer growth in people with advanced Merkel cell cancer that didn't respond to prior treatment. About 50 participants will receive either the combi…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This phase 2 study tests a combination of two drugs—talimogene laherparepvec (T-VEC), a virus that attacks cancer cells, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in 41 adults with advanced sarcoma that has spread or cannot be removed by surger…

This pilot study tests whether injections of platelet-rich plasma (PRP) made from a patient's own blood can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants receive three injections over four months, and researchers …

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer has spread to lymph nodes and who have already had surgery or radiation. About 100 adults will receive either avelumab or a placebo every two we…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…

This phase 2 trial is testing whether giving a combination of two drugs—lenvatinib and pembrolizumab—before surgery can help people with Merkel cell carcinoma. The study involves 26 participants with stage II, III, or IV disease. The main goal is to see if the treatment leads to …

This study tests a combination of targeted radiation (CART) and the immunotherapy drug avelumab in 18 people with advanced Merkel cell carcinoma that has spread or cannot be removed by surgery. The goal is to see if this approach can slow or stop the cancer from growing. Particip…

This study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…

This study tests whether adding focused radiation to a two-drug immunotherapy combination works better than the drugs alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. About 50 adults with cancer that has spread or cannot be removed will rec…

This early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. T…

This study tests giving the chemotherapy drug paclitaxel before and during radiation therapy for people with cutaneous angiosarcoma, a rare and aggressive skin cancer. The goal is to shrink the tumor before surgery and improve how long patients live without the cancer coming back…

This study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…

This study looks at blood samples from 20 adults with melanoma or other skin cancers to see if certain markers in the blood can predict how well treatment works or how long someone lives. Researchers will compare these markers to standard measures like tumor response and survival…

This small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…